Sildenafil clearance is a pharmacokinetic parameter describing how efficiently unchanged sildenafil is removed from the circulating parent-drug pool. Clearance is expressed as a volume per unit time, so it describes removal efficiency rather than the number of milligrams eliminated during a particular interval.
For sildenafil, clearance is predominantly metabolic. Current labeling identifies CYP3A as the major metabolic route and CYP2C9 as a minor route. Historical FDA clinical-pharmacology analysis of oral sildenafil reported an apparent oral clearance of approximately 41 L/h, an important value that should be interpreted as CL/F rather than automatically treated as true systemic clearance.
This page focuses on clearance as a sildenafil-specific PK parameter: how it is estimated, how metabolism contributes, why clearance influences AUC, how it differs from half-life and why oral apparent clearance must be separated from systemic clearance. The time course of concentration decline belongs on the sildenafil half-life page, while enzyme-mediated transformation is examined separately on the sildenafil metabolism page.
In pharmacokinetics, clearance describes the efficiency with which unchanged sildenafil is removed from a defined circulating compartment. Conceptually, it represents the volume of plasma from which the drug would be completely removed per unit time to account for the observed elimination rate.
Clearance is related to elimination rate but is not the same quantity. At a particular concentration, elimination rate can be conceptualized as clearance multiplied by concentration. If concentration changes while clearance remains approximately constant, the absolute amount of drug removed per hour also changes.
Within the broader sildenafil pharmacokinetic framework, clearance is one of the major determinants of systemic exposure. Lower clearance generally allows concentrations to remain higher for longer, while higher clearance removes parent sildenafil more efficiently.
| Concept | Primary Meaning |
|---|---|
| Clearance | Efficiency of parent-drug removal, typically expressed as volume per time. |
| Elimination rate | Amount of drug removed per unit time at the current concentration. |
| Half-life | Time scale associated with concentration decline. |
| Excretion | Physical removal of drug-related material from the body. |
Clearance is usually expressed in units such as liters per hour. This does not mean liters of blood or plasma physically leave the body. The volume is a pharmacokinetic abstraction linking measured concentration with the rate at which drug disappears from the circulating compartment.
For example, an apparent oral sildenafil clearance reported as 41 L/h does not mean 41 liters of plasma are literally filtered every hour. It means the observed dose-to-exposure relationship behaves as though sildenafil were completely removed from that conceptual plasma volume during each hour, after accounting for the way the oral parameter is defined.
This volume-per-time dimension distinguishes clearance from concentration, which is amount per volume; elimination rate, which is amount per time; and half-life, which is expressed only as time.
| Quantity | Typical Dimension | Interpretation |
|---|---|---|
| Concentration | Amount / volume | How much sildenafil is present in sampled plasma. |
| Elimination rate | Amount / time | How much parent drug is removed during an interval. |
| Clearance | Volume / time | Efficiency of systemic drug removal. |
| Half-life | Time | Time scale of concentration decline. |
Systemic clearance refers to removal of parent sildenafil after the drug has entered systemic circulation. This concept is most directly estimated when systemic input is known independently of oral bioavailability, such as with intravenous pharmacokinetic data.
Sildenafil should not be assigned one universal clearance value without identifying the route, population and model. Historical FDA analyses reported apparent oral clearance of approximately 41 L/h after single oral dosing, whereas intravenous and population analyses have produced different estimates because they measure systemic clearance more directly and can involve different study populations.
This distinction prevents a common error: quoting 41 L/h simply as 'the sildenafil clearance' without identifying it as an apparent oral estimate. Oral CL/F contains both true clearance and the influence of systemic bioavailability.
| Clearance Expression | Interpretation |
|---|---|
| Systemic CL | Removal efficiency after sildenafil has entered systemic circulation. |
| Oral CL/F | Apparent clearance estimated from oral dose and exposure. |
| Historical oral sildenafil estimate | Approximately 41 L/h for apparent oral clearance in an FDA clinical-pharmacology analysis. |
Metabolism is the dominant mechanism by which unchanged sildenafil is removed from the parent-drug pool. Current labeling identifies CYP3A as the major route and CYP2C9 as a minor route of sildenafil metabolism.
When sildenafil undergoes metabolic transformation, the parent molecule no longer contributes to measured parent-drug plasma concentration even though metabolites can remain pharmacologically or analytically relevant. The major circulating N-desmethyl metabolite is itself active and undergoes further metabolism.
Metabolism and clearance nevertheless remain different concepts. Enzyme reactions describe how sildenafil is chemically transformed; clearance quantifies the efficiency of overall parent-drug removal. The pathways themselves are covered on the sildenafil metabolism page, with CYP-specific detail on the sildenafil CYP3A4 guide.
| Feature | Metabolism | Clearance |
|---|---|---|
| Primary concept | Chemical transformation | Removal efficiency |
| Major sildenafil pathway | CYP3A | Reflects combined parent-drug removal processes |
| Minor metabolic pathway | CYP2C9 | Contributes indirectly through metabolism |
| Expressed as volume per time? | No | Typically yes |
Clearance, metabolism and excretion describe different parts of sildenafil disposition. Parent sildenafil is cleared predominantly through metabolism, after which drug-related material is ultimately removed from the body.
Current labeling reports that after oral or intravenous administration, drug-related material is recovered predominantly in feces, at approximately 80% of the administered oral dose, and to a lesser extent in urine, at approximately 13%. Importantly, these values refer predominantly to metabolites rather than unchanged parent sildenafil.
The 80% and 13% recovery figures therefore should not be interpreted as meaning that 80% of parent sildenafil clearance is 'fecal clearance' and 13% is 'renal clearance.' They describe routes of final excretion of drug-related material after metabolism, not the fractional systemic clearance of unchanged sildenafil.
| Process | Primary Outcome |
|---|---|
| Metabolism | Transforms parent sildenafil into metabolites. |
| Parent-drug clearance | Removes unchanged sildenafil from the circulating parent-drug pool. |
| Fecal recovery | Approximately 80% of administered oral dose, predominantly as metabolites. |
| Urinary recovery | Approximately 13% of administered oral dose, predominantly as metabolites. |
Clearance and AUC are mathematically linked under approximately linear pharmacokinetic conditions. For systemic administration, AUC is related to dose divided by clearance; after oral administration, systemic availability must also be considered, giving the conceptual relationship AUC = F × Dose / CL.
This means that if dose and systemic input are otherwise comparable, reduced sildenafil clearance produces greater AUC because parent drug is removed less efficiently. Conversely, increased clearance lowers exposure by removing sildenafil more rapidly from the systemic compartment.
AUC cannot be used as a pure measure of clearance after oral administration unless bioavailability and dose are considered. Integrated exposure is covered on the sildenafil AUC page, while the broader determinants of exposure belong on the sildenafil exposure page.
| PK Condition | Expected Direction of Exposure, Other Factors Equal |
|---|---|
| Lower clearance | Higher AUC. |
| Higher clearance | Lower AUC. |
| Higher bioavailability | Can increase oral AUC without a clearance change. |
| Higher dose under linear PK | Increases AUC without necessarily changing clearance. |
Clearance and half-life are related but fundamentally different parameters. Clearance describes removal efficiency, while half-life describes the time required for concentration to decline by one-half during a defined elimination phase.
In a simplified one-compartment relationship, elimination half-life depends on both distribution volume and clearance, often represented conceptually as t1/2 ≈ 0.693 × V / CL. This is why two drugs or PK models with the same clearance do not necessarily have the same half-life.
Sildenafil labeling generally describes terminal half-life for sildenafil and its major active metabolite as about 4 hours. That number cannot be derived from a clearance value alone without using the appropriate distribution and model context. The time-based interpretation belongs on the sildenafil half-life page.
| Feature | Clearance | Half-Life |
|---|---|---|
| Primary question | How efficiently is sildenafil removed? | How rapidly does concentration decline? |
| Dimension | Volume / time | Time |
| Depends directly on distribution volume? | No | Yes, in the relationship between clearance and concentration decline |
| Typical sildenafil context | Route- and model-dependent clearance estimate | Terminal half-life about 4 hours in labeling |
Clearance removes drug from the systemic parent-drug pool, whereas distribution determines how sildenafil is partitioned between plasma and tissues. A change in plasma concentration can therefore occur because drug has been eliminated or because it has redistributed into another compartment.
Sildenafil has a reported mean steady-state volume of distribution of approximately 105 L, indicating substantial distribution beyond the sampled plasma space. This distribution context helps explain why concentration decline and clearance cannot be interpreted as though sildenafil remained confined to the bloodstream.
Half-life emerges from the relationship between elimination and distribution rather than clearance alone. Distribution concepts, including protein binding and apparent volume, are covered on the sildenafil distribution page.
| Process | Effect on Plasma Concentration |
|---|---|
| Distribution into tissues | Can reduce plasma concentration without eliminating drug from the body. |
| Metabolic clearance | Removes unchanged parent sildenafil from the systemic pool. |
| Redistribution | Can move previously distributed drug back toward plasma. |
| Steady-state distribution volume | Approximately 105 L in labeling context. |
Clearance contributes throughout the systemic concentration-time profile, but its effect is easiest to conceptualize during the declining portion of the curve. The observed slope still reflects the combined behavior of elimination and distribution rather than clearance operating in isolation.
During the early post-dose period, continuing absorption can mask elimination because drug is still entering systemic circulation while it is simultaneously being distributed and cleared. Around and after the peak, systemic input decreases and elimination becomes progressively more visible in the measured concentration profile.
The terminal phase is commonly used to characterize elimination-related behavior, but terminal slope is not itself clearance. The complete interaction of absorption, distribution and decline is explained on the sildenafil concentration-time page.
| Curve Region | Relevant Processes |
|---|---|
| Rising phase | Absorption exceeds net concentration-lowering processes. |
| Peak region | Systemic input and concentration-lowering processes approach balance. |
| Post-peak phase | Distribution and elimination increasingly dominate. |
| Terminal phase | Late decline helps characterize elimination-related parameters but is not itself a direct clearance measurement. |
Sildenafil clearance is not identical in every person or under every pharmacokinetic condition. Age, hepatic function, severe renal impairment and changes in CYP-mediated metabolism can alter the removal of parent sildenafil and therefore change systemic exposure.
Current labeling provides concrete examples. Healthy volunteers aged 65 years or older had reduced sildenafil clearance and approximately 84% higher total sildenafil AUC than younger volunteers. CYP3A inhibitors can also reduce sildenafil clearance, while enzyme induction can increase metabolic clearance.
These differences illustrate why clearance is more than an abstract PK term: a change in clearance can materially alter AUC and concentration profiles. The broader sources of between-subject variability remain covered on the sildenafil PK variability page.
| Source of Variation | Potential Relationship to Clearance |
|---|---|
| Older age | Reduced clearance has been observed in healthy elderly volunteers. |
| CYP3A inhibition | Can reduce metabolic clearance and increase sildenafil exposure. |
| CYP induction | Can increase metabolic clearance and reduce exposure. |
| Hepatic impairment | Can reduce sildenafil clearance. |
| Severe renal impairment | Associated with reduced sildenafil clearance despite predominantly metabolic parent-drug elimination. |
Hepatic function is directly relevant to sildenafil clearance because metabolism is the principal route of parent-drug removal. Reduced hepatic metabolic capacity can therefore lower clearance and increase circulating exposure.
In volunteers with mild-to-moderate hepatic impairment classified as Child-Pugh A or B, sildenafil clearance was reduced. Labeling reports approximately 85% higher AUC and 47% higher Cmax compared with age-matched volunteers without hepatic impairment.
Those percentages are population-specific PK observations rather than a universal conversion between liver function and clearance. Detailed subgroup interpretation belongs on the sildenafil hepatic impairment pharmacokinetics page.
Sildenafil demonstrates why urinary excretion and systemic parent-drug clearance should not be equated. Only a minority of administered drug-related material is recovered in urine, and parent sildenafil is removed predominantly through metabolism rather than direct renal excretion of unchanged drug.
Nevertheless, severe renal impairment can alter sildenafil pharmacokinetics through broader physiological effects. In volunteers with creatinine clearance below 30 mL/min, sildenafil clearance was reduced and both AUC and Cmax were approximately doubled compared with age-matched volunteers with normal renal function.
Mild and moderate renal impairment did not show the same change in the cited single-dose study. The dedicated sildenafil renal impairment pharmacokinetics page examines these subgroup findings in depth.
| Concept | Interpretation |
|---|---|
| Urinary recovery | Approximately 13% of administered oral dose as drug-related material, predominantly metabolites. |
| Parent-drug clearance | Predominantly metabolic rather than direct renal excretion. |
| Severe renal impairment | Reduced clearance with approximately twofold increases in AUC and Cmax in labeling data. |
Clearance is calculated from administered dose and systemic exposure rather than measured directly in a single blood sample. When drug is administered intravenously and systemic input is complete, clearance can be conceptualized as CL = Dose / AUC.
After oral administration, only a fraction of the dose reaches systemic circulation unchanged. If absolute bioavailability is not separately incorporated, the directly calculated parameter is apparent oral clearance, CL/F = oral Dose / AUC.
This distinction is especially relevant for sildenafil because mean absolute oral bioavailability is approximately 41%. Historical FDA clinical-pharmacology analysis reported apparent oral clearance of approximately 41 L/h; the '/F' component means that value should not automatically be interpreted as the true systemic clearance of sildenafil.
| Study Element | Role in Clearance Estimation |
|---|---|
| IV dose | Allows direct systemic input to be related to AUC. |
| Oral dose | Requires bioavailability context. |
| AUC | Provides integrated exposure used in the clearance relationship. |
| CL | Systemic clearance when systemic input is known. |
| CL/F | Apparent oral clearance when bioavailability is incorporated in the denominator. |
Systemic clearance and apparent oral clearance answer related but different questions. Systemic clearance describes removal efficiency after drug reaches systemic circulation, whereas CL/F is estimated from an oral dose and therefore contains both clearance and bioavailability in the parameter.
If oral bioavailability changes while true systemic clearance remains unchanged, CL/F can also change because F appears in the denominator. This is why apparent oral clearance should not be interpreted as a pure measure of eliminating-organ function.
For sildenafil, the historical value of approximately 41 L/h is best described as an apparent oral clearance estimate rather than a universal systemic clearance value. The systemic-availability component of this distinction is explained on the sildenafil bioavailability page.
| Clearance Concept | Interpretive Focus |
|---|---|
| Systemic clearance (CL) | Removal efficiency once sildenafil is systemically available. |
| Apparent oral clearance (CL/F) | Oral dose-to-AUC relationship influenced by both CL and bioavailability. |
| Historical sildenafil CL/F | Approximately 41 L/h in an FDA single-dose clinical-pharmacology analysis. |
| Bioavailability | Mean absolute oral sildenafil bioavailability is approximately 41% in labeling. |
Sildenafil clearance is best interpreted as the removal-efficiency component of the complete pharmacokinetic system rather than as a standalone number. The route of administration, bioavailability, population and PK model determine what a reported clearance parameter actually represents.
The major sildenafil-specific facts fit together coherently: parent drug is cleared predominantly through CYP3A-mediated metabolism with a smaller CYP2C9 contribution; historical oral analysis reported CL/F of approximately 41 L/h; terminal half-life is about 4 hours; and drug-related material is ultimately recovered mainly in feces as metabolites.
A clearance value becomes most informative when considered alongside AUC, bioavailability, distribution volume and half-life. For the complete ADME framework, the sildenafil pharmacokinetics hub connects clearance with absorption, distribution, metabolism, exposure and elimination.
| Research Question | Most Relevant PK Concept |
|---|---|
| How efficiently is sildenafil removed? | Systemic clearance or apparent oral clearance, depending on the study. |
| How much integrated systemic exposure occurs? | AUC |
| How is parent sildenafil chemically transformed? | Metabolism |
| How quickly does terminal concentration decline? | Half-life |
| What fraction of an oral dose becomes systemically available? | Bioavailability |
Sildenafil clearance describes the efficiency with which unchanged parent sildenafil is removed from systemic circulation. It is usually expressed as a volume per unit time rather than as an amount of drug eliminated.
A historical FDA clinical-pharmacology analysis reported an apparent oral sildenafil clearance of approximately 41 L/h. This is a CL/F value derived after oral administration and should not automatically be treated as a universal true systemic clearance value.
Sildenafil is cleared predominantly through hepatic metabolism, with CYP3A representing the major metabolic route and CYP2C9 a minor route. Drug-related material is subsequently recovered mainly in feces and to a lesser extent in urine.
No. Clearance describes removal efficiency, while half-life describes the time scale of concentration decline and depends on both clearance and distribution characteristics. Sildenafil has a terminal half-life of about 4 hours in current labeling.
When dose and systemic input are otherwise comparable, lower clearance produces higher AUC because sildenafil is removed less efficiently. Higher clearance generally reduces AUC.
No. Parent sildenafil is cleared predominantly through metabolism. About 13% of an administered oral dose is recovered in urine as drug-related material, predominantly metabolites; this urinary recovery percentage should not be interpreted as the fraction of parent sildenafil cleared directly by the kidneys.